Posted by
Ketamine-like drug for depression could get UK licence within the year

Ketamine-like drug for depression could get UK licence within the year

Esketamine could initially become available through private clinics but potential side effects raise concerns. A ketamine-like drug that could be licensed in the UK as soon as November could transform treatment for severe depression, one of the country’s leading psychiatrists has said. The drug, called esketamine, which is administered through a nasal spray, would be […]

Posted by
Treatment of fibromyalgia in adults not responsive to initial therapies

Treatment of fibromyalgia in adults not responsive to initial therapies

INTRODUCTION Fibromyalgia is a chronic pain disorder that is often difficult to treat. Effective interventions include a number of nonpharmacologic and pharmacologic therapies that are often provided in combination. Patients with fibromyalgia generally respond best to a multidisciplinary, individualized treatment program that incorporates the primary treating clinician and other healthcare providers, including physical medicine, rehabilitation, […]

Posted by
Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder

Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder

Aimee M. HunterMichael J. MinzenbergIan A. CookDavid E. KrantzJennifer G. LevittNatalie M. RotsteinShweta A. ChawlaAndrew F. LeuchterFirst published: 02 April 2019 https://doi.org/10.1002/brb3.1275 Cited by: 1 Abstract Background Repetitive Transcranial Magnetic Stimulation (rTMS) is commonly administered to Major Depressive Disorder (MDD) patients taking psychotropic medications, yet the effects on treatment outcomes remain unknown. We explored how concomitant medication use relates […]

Posted by
Cannabis: Doctors tell FDA to get out of the weeds

Cannabis: Doctors tell FDA to get out of the weeds

Publish date: May 31, 2019 By Kari Oakes  Clinical Neurology News FROM AN FDA PUBLIC HEARING The Food and Drug Administration held its first-ever public hearing about products containing cannabis or cannabis-derived compounds – and it got an earful. Hearing from over 100 individuals, the all-staff FDA panel was asked repeatedly to take the lead in bringing order […]

Posted by
Marijuana during prenatal OUD treatment increases premature birth

Marijuana during prenatal OUD treatment increases premature birth

Publish date: April 28, 2019By M. Alexander Otto REPORTING FROM PAS 2019 BALTIMORE – Marijuana is a not a good idea during pregnancy, and it’s an even worse idea when women are being treated for opioid addiction, according to an investigation from East Tennessee State University, Mountain Home. Marijuana use may become more common as legalization rolls out […]

Posted by
Intranasal esketamine combo tied to symptom improvement

Intranasal esketamine combo tied to symptom improvement

Concern raised about drug’s abuse potential Publish date: May 21, 2019 By Jim Kling REPORTING FROM APA 2019 SAN FRANCISCO – In treatment-resistant depression, a switch to a new antidepressant combined with inhaled esketamine (Spravato) led to better symptom improvement than did a switch to a new antidepressant plus placebo, results from a new trial show. The […]

Posted by
Repetitive TMS Effective for Comorbid Major Depressive Disorder, Anxiety

Repetitive TMS Effective for Comorbid Major Depressive Disorder, Anxiety

Repetitive transcranial magnetic stimulation (rTMS) showed efficacy in patients with major depressive disorder (MDD) and comorbid anxiety, according to results from a study published in the Journal of Affective Disorders. Researchers conducted a single-site, nonrandomized, comparison study of 248 patients who received rTMS therapy for treatment-resistant MDD. Among those included, 172 participants had a minimum of 1 comorbid […]